Are there any adverse reactions to watch for?

Possible adverse reactions include gastrointestinal flora disorder, superinfection, and certain renal toxicity.

What are the available package specifications?

Available in 1.0g or 4.0g vials, with 20 vials per carton.

Does this product offer customization services?

Yes, the manufacturer provides both OEM and ODM services for this product.

Ceftiofur Sodium for Veterinary Use Anti Pleuropneumoniae Actinobacillus Drugs

Name: Ceftiofur Sodium for Veterinary Use Anti Pleuropneumoniae Actinobacillus Drugs
Brand: Shandong Sinder Technology Co., Ltd
SKU: 2088492362

Shandong, ChinaShandong Sinder Technology Co., Ltd

US$0.10-30.00

3,500 vial

Product profile

Customization

Available

Varieties

Infectious Disease Prevention Medicine

Component

Chemical Synthetic Drugs

Model NO.

Ceftiofur Sodium

Type

The First Class

Pharmacodynamic Influential Factors

Animal Species

Storage Method

Light Proof

Veterinary Reg. No.

220042021

Main Ingredient

Ceftiofur Sodium

Character

White to Light Yellow Powder or Sparse Block

Usage

Injection

Expiry Date

2 Years

GMP

22018

Transport Package

Box

Specification

4g/vial

Trademark

SINDER

Origin

Sichuan, China

HS Code

3004209099

Production Capacity

100000L/Year

Key features

Broad-Spectrum Antibacterial Action: Effective against gram-positive and gram-negative bacteria including Actinobacillus pleuropneumoniae.

Strong Antibacterial Activity: Exhibits stronger activity against streptococci than fluoroquinolones and stronger than ampicillin.

Rapid Absorption via Injection: Not absorbed orally but rapidly absorbed via intramuscular and subcutaneous injection routes.

Long-Lasting Drug Concentration: High drug concentration in blood and tissue with effective duration lasting a very long period.

Synergistic Drug Interactions: Shows synergistic effects when administered together with penicillin and aminoglycoside drugs.

Zero Withdrawal Time for Chicks: Safe for use in 1-day-old chicks with a withdrawal time of 0 days.

Comprehensive GMP Compliance: Manufactured under strict GMP standards with approval number 22018.

OEM and ODM Services Available: Manufacturer offers both OEM and ODM customization services for veterinary products.

Company profile

Shandong Sinder Technology Co., Ltd

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2013-03-01 CertifiedNearest Port: Qingdao PortAverage Response Time: >24h CertifiedTerms of Payment: LC, T/T

AI-Powered supplier vetting

SummaryShandong Sinder Technology Co., Ltd. is a China-based foreign joint venture established in 1999, with 1,200 employees and operations focused on animal health, vaccines, medicines, feed additives, and herbal products. The available information indicates substantial production capacity, including nine production lines and stated annual outputs for vaccines, medicines, feed additives, and herbal products. It holds ISO9001:2015 and ISO14001:2015 certifications, and its disclosed R&D and quality-control staffing supports technical and quality capabilities. Innovation evidence includes large-scale cell suspension culture for highly pathogenic avian influenza vaccines. Export activity is documented from 2013, with markets across multiple regions, although exports represent only 1%–10% of total sales. Evidence is insufficient to assess after-sales service, customization capability, and broader customer-case depth. Financial credibility cannot be assessed because financial figures are excluded.

Supplier typeThe supplier is identified as Shandong Sinder Technology Co., Ltd., a China-based foreign joint venture established in 1999. Its business scope covers health and medicine, chemicals, agriculture and food, with product keywords centered on animal vaccines, veterinary medicines, feed additives, detection kits, and herbal products.

CertificationsThe supplier information explicitly lists ISO9001:2015 and ISO14001:2015 certificates, along with other unspecified certifications. This provides direct evidence of certified quality-management and environmental-management systems.

R&D capabilityThe supplier reports 154 R&D engineers, and its company description states that it was the first worldwide to achieve large-scale cell suspension culture of highly pathogenic avian influenza vaccine for animals. The disclosed production workshop was also described as the first approved by China’s Ministry of Agriculture and Rural Affairs for this technology, providing strong evidence of specialized innovation capability.

Production capacityThe supplier operates nine production lines, has a 73,279 m² manufacturing plant, employs 1,200 people, and reports annual outputs of 2,000 tons each for live and killed vaccines, 4,000 tons of medicine, 10,000 tons of feed additives, and 5,000 tons of herbal products. These stated facilities, workforce, production lines, and output figures directly support substantial production capability.

Client casesThree transaction records identify CÔNG TY TNHH THƯƠNG MẠI ANIVACC in Vietnam as an associated buyer, involving PCV2-related pig vaccine products and at least one recorded transaction. This confirms a documented buyer relationship, but the evidence is limited to one named buyer and does not demonstrate a broad portfolio of customer cases or project outcomes.